Income loss after a cancer diagnosis in Germany: An analysis based on the socio‐economic panel survey

Hernández, Diego; Schlander, Michael

doi:10.1002/cam4.3913

Cited by 17 publications

(7 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The negative effect of a cancer diagnosis on income is already established in the literature,21 22 with some evidence on specific cancers such as breast cancer 23 24. Literature suggests that the increase in part-time contracts and the reduction of working hours as explanations for the loss in income 22 25 26. However, in our case, the income reduction does not seem to be related to an increase in part-time contracts as the analyses performed on the subsample of full-time workers confirm the overall trend.…”

Section: Discussionmentioning

confidence: 85%

See 1 more Smart Citation

Short-term effect of colorectal cancer on income: analysis of an Italian cohort

Farina

Rosso

Dansero

et al. 2023

J Epidemiol Community Health

View full text Add to dashboard Cite

IntroductionThe ability to return to work after a cancer diagnosis is a key aspect of cancer survivorship and quality of life. Studies have reported a significant risk of income loss for cancer survivors; however, there is limited evidence of the Italian context.MethodsThe Work Histories Italian Panel (WHIP)-Salute database was used to select a cohort of incident cases of colorectal cancer (CRC) among workers in the private sector, based on hospital discharges. A propensity score matching was used to find a balanced control group for several confounders. Ordinary least square and logistic regressions were used to estimate the effect of a CRC diagnosis on annual income and the probability of switching from a full-time contract to a part-time one considering 3 years after the diagnosis.ResultsOverall, we identified 925 CRC incident cases from 2006 until 2012. Our results confirm a statistically significant reduction in survivors’ income compared with controls. This reduction was greater in the first year and then tend to decrease, with an average income loss over 3 years of about €12 000. Stratified analyses by sex and position confirmed the overall trend while indicating a strong effect modification. Regarding the switching from full-time to part-time employment, the results were never significant.ConclusionIncome loss does not seem to be related to an increase in part-time contracts, but rather to survivors’ reduced work capacity following the invasive treatments. Further research is needed to investigate the complex dynamics behind this association.

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Discussionmentioning

confidence: 94%

Short-term effect of colorectal cancer on income: analysis of an Italian cohort

Farina

Rosso

Dansero

et al. 2023

J Epidemiol Community Health

View full text Add to dashboard Cite

show abstract

“…Finally, there is also a financial burden on patients arising from out-of-pocket costs for DS that cannot be ignored. Many cancer patients suffer from financial hardship as a consequence of their illness due to diverse additional costs [ 42 ], a reduction in working hours [ 43 ], a loss of revenue and an increased likelihood of unemployment [ 43 ]. Around 20–30% of cancer survivors do not return to the workplace [ 42 ].…”

Section: Discussionmentioning

confidence: 99%

Dietary supplement intake in women with breast cancer before and after diagnosis: results from the SUCCESS C trial

Hauner,

Mang,

Donik

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Background There is little evidence that dietary supplements are beneficial for patients with breast cancer; therefore, they are usually not recommended by treatment guidelines. The aim of the present analysis was to assess the prevalence of dietary supplement (DS) intake among women before and after a breast cancer diagnosis. Methods Participants in the SUCCESS C lifestyle intervention study, a randomized controlled trial in women with newly diagnosed intermediate- to high-risk breast cancer, completed two questionnaires on dietary supplement intake 24 months (QS1) and 48 months (QS2) after beginning the lifestyle intervention. The study was registered on 12.17.2008 under the EU Clinical Trials Register https://www.clinicaltrialsregister.eu/, trial registration number: 2008-005453-38. The questionnaires collected data on DS intake during the 5-year period prediagnosis (QS1) and in the period postdiagnosis (QS2). Multivariate logistic regression models were fitted to examine differences in DS intake between the two intervention groups. The groups were then pooled to examine differences in DS use between the prediagnostic and postdiagnostic period. Results A total of 320 questionnaires from 58.5% of intervention group completers and 416 questionnaires from 46.6% of low-level intervention group completers were included in the analysis. Overall, 20.2% of all respondents reported taking DS prior to their diagnosis. After a cancer diagnosis, the percentage of women taking DS significantly increased to 56.4% (p for time effect < 0.0001). No differences in DS intake between the intervention groups were observed. Single or combined preparations of vitamins and minerals/trace elements were the most frequently reported supplements. Notably, a 9-fold increase in vitamin D intake was reported postdiagnosis, where the proportion of women increased from 3.8 to 34.5%. Conclusion A 3-fold increase in the reported intake of dietary supplements was seen in women after a breast cancer diagnosis. These observations underscore the need to incorporate patient education surrounding the use of dietary supplements in a treatment care plan, particularly addressing the negligible benefits as well as the potential risks and treatment interactions.

show abstract

“…There is a significant body of recent literature examining the financial and social impact of a cancer diagnosis on patients and their families related to cancer treatment and follow-up care. These studies have shown impacts related to out-of-pocket costs (OOPC) [1–7], lost income for patients [8–14,15 ▪ ,16,17,18 ▪ ,19 ▪ ] or both [20–23,24 ▪ ,25,26,27 ▪ ,28–30]. In some cases, studies are focused on specific cancers including breast [4,18 ▪ ,22,23,31], colorectal [22,23,32,33], lung [22,23], prostate [3,22,23,25], other solid tumours [16,21,34] as well as hematologic malignancies [26].…”

Section: Recent Updates On Patients’ Financial Burden/toxicitymentioning

confidence: 99%

“…The objective of this article is to provide a summary of recent literature regarding the factors that influence access to care in cancer, with a particular focus on economics and sociocultural factors. This is a rapid review of the literature published in the past (12)(13)(14)(15)(16)(17)(18) months related to patient and family financial burden or financial toxicity. The review includes articles that examine these issues from an ethnic or cultural lens, including those populations who are identified as marginalized, and those with low education or low socioeconomic status.…”

Section: Introductionmentioning

confidence: 99%

Unequal distribution of financial toxicity among people with cancer and its impact on access to care: a rapid review

Longo

Fitch

2021

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

Purpose of reviewResearch demonstrates that patients and their families often carry a good portion of the economic burden during and following cancer treatment, frequently resulting in implications for access to care. This rapid review summarizes how this knowledge has evolved in recent years.Recent findingsThe number of articles on patient financial burden is increasing, suggesting awareness about the growing impact of economic burden on patients. This is particularly evident when discussing out-of-pocket costs, and lost work for patients/caregivers. However, there is an increasing focus on ‘foregone care’ and ‘financial distress’. Additionally, emerging literature is examining policies and approaches to screen and/or mitigate these patient financial risks, thereby improving access to care. There is also increasing focus on populations that shoulder a disproportionate financial burden, including ethnic minorities (blacks, Asians, Latinos) as well as those with lower socioeconomic status. Additionally, there is evidence that this burden also affects the middle class.SummaryAs healthcare budgets become stretched, especially during a pandemic, supportive programs benefiting the less fortunate often shrink, which impacts access to care. The emerging research on strategies with government or institutions to mitigate these burdens and access issues are both welcome and needed.

show abstract

Income loss after a cancer diagnosis in Germany: An analysis based on the socio‐economic panel survey

Cited by 17 publications

References 42 publications

Short-term effect of colorectal cancer on income: analysis of an Italian cohort

Short-term effect of colorectal cancer on income: analysis of an Italian cohort

Dietary supplement intake in women with breast cancer before and after diagnosis: results from the SUCCESS C trial

Unequal distribution of financial toxicity among people with cancer and its impact on access to care: a rapid review

Contact Info

Product

Resources

About